LS Mtron Participates in ‘Agritechnica 2019’ Accelerating Its Advance into Europe
28.11.2019 11:00:00 EET | Business Wire | Press release
LS Mtron (CEO Andy Kim) announced on November 28 that it had participated in ‘Agritechnica 2019’ held in Hanover, Germany from November 10 through the 16.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191128005173/en/
LS Mtron of Korea, specializing in industrial machines and state-of-the-art components, participated in ‘Agritechnica 2019’. The company has participated in the exhibition since 2015. This year, LS Mtron had a booth covering 205 square meters to showcase its products. Under banners reading “Change Your Standard,” LS Mtron exhibited products that stressed both ‘reliability’ and ‘rationality’. In particular, tractors featuring innovative futuristic design and technology were favorably received by visitors. (Photo: Business Wire)
Under banners reading “Change Your Standard,” LS Mtron exhibited products that stressed both ‘reliability’ and ‘rationality’. In particular, tractors featuring innovative futuristic design and technology were favorably received by visitors.
In 2003, LS Mtron was spun off from LG Group as an affiliate specializing in industrial machines and state-of-the-art components. Last year, sales amounted to KRW1.1 trillion. LS Mtron, with its annual production capacity of 50,000 units, has the largest share of the Korean tractor market. The company also exports to more than 40 countries, including the US, Brazil, China, etc., with its global production and sales bases playing key roles.
Significantly, last year, LS Mtron received the ‘Tractor of the Year’ award at the North American Equipment Dealers Association’s ‘Dealer’s Choice’ awards for the 5th consecutive years. In addition, LS Mtron is ‘Korea’s No.1 Tractor’ maker that is using ICT technology to lead the agricultural machinery industry in remote diagnostic services and cutting-edge autonomous tractor technologies.
This year, LS Mtron had a booth covering 205m2 to showcase its products in ‘Agritechnica 2019’. The slogan for the event ‘Change Your Standard’ was chosen to present maximum reliability and rationality to European customers and change the anchor purchases with excellent product fundamentals, innovative design, compelling performance, full support for dealers, and supplying parts at the right place at the right time.
LS Mtron introduced 7 models ranging from an 18ps Sub-compact model to the 150ps Row-crop model which can appeal to European customers. The futuristic ‘MTX (tentative)’ concept tractor is thought to have taken the streamlined design of existing products a step further. The company has applied a strong and sharp design language with headlamps resembling the fierce eyes of an angry bull that clearly say that LS Mtron products can provide ‘powerful and faithful work performance’. The Utility tractor, 100ps ‘XP’ model, scheduled to be launched in Europe in 2020 especially drew the attention of visitors. The XP tractor, based on its powerful engine and cutting-edge technology, makes it possible to move forward and backward easily without the manual operation of clutches when using the improved power shuttle. And as it comes standard with LED headlamps instead of halogen, its workability at night has also been improved.
In particular, during the exhibition, LS Mtron entered into an MOU for the development of e-Tractors with Austria’s AVL, the world’s best powertrain development and testing company. The two companies are planning to capitalize on this MOU to develop Sub-Compact e-Tractors and produce highly-efficient and eco-friendly tractors. LS Mtron will proactively present the direction of its eco-friendly models of the future to the European market and introduce a broader lineup of various models to make inroads into the lawn & garden and landscaping markets.
LS Mtron is planning to leverage its participation in the exhibition to develop new models and technologies customized for Europe. The company has established a roadmap for the launch of new models starting with the new premium MT2 and utility tractors in 2020 and plans to proactively respond to environmental protection and regulatory changes by successively launching new models based on the Stage V engine in 2021. In January 2020, LS Mtron will become the first Korean company in the industry to restrict the use of hazardous materials containing phthalates, thereby promoting the safety of customers and eco-friendliness.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191128005173/en/
Contact information
LS Mtron
Jae Woo Lee
+82-31-8045-9667
unforgiven81@lsmtron.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom